<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174510</url>
  </required_header>
  <id_info>
    <org_study_id>D1070002</org_study_id>
    <nct_id>NCT02174510</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects</brief_title>
  <official_title>A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xuhui Central Hospital, Shanghai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetic (PK) characteristics of lurasidone after single oral
      administration of different doses in healthy Chinese subjects.

      To evaluate the safety and tolerability of lurasidone after single oral administration of
      different doses in healthy Chinese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single administration, double-blinded, placebo-controlled (3 subjects in each group will take
      placebo) and 3 dose groups (20 mg, 40 mg and 80 mg). There are three groups which are 20mg
      lurasidone or placebo, 40mg lurasidone or placebo and 80mg lurasidone or placebo.

      This study comprises a screening period (between signing of the informed consent form and Day
      -2), baseline period (Day -1), treatment period (Days 1-3) and ending of study examination
      period (Days 8-11 after the last sample collection for PK evaluation).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lurasidone Cmax</measure>
    <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
    <description>Cmax：Maximum (peak) observed drug serum concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone AUC</measure>
    <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
    <description>AUC：Area under the serum concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone Tmax</measure>
    <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
    <description>Tmax：Time to maximum (peak) drug serum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone λZ</measure>
    <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
    <description>λZ：Elimination rate constant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone t1/2</measure>
    <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
    <description>t1/2 :Biological half life correlated with the elimination rate constant (kel) of semi-logarithmic concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone MRT</measure>
    <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
    <description>MRT：Mean residence time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone CL/F</measure>
    <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
    <description>CL/F：Apparent total clearance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lurasidone VZ/F</measure>
    <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
    <description>VZ/F: Apparent volume of distribution at terminal phase (correlated with λz)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>20mg lurasidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40mg lurasidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80mg lurasidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20mg lurasidone</intervention_name>
    <description>single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.</description>
    <arm_group_label>20mg lurasidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40mg lurasidone</intervention_name>
    <description>single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.</description>
    <arm_group_label>40mg lurasidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80mg lurasidone</intervention_name>
    <description>single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.</description>
    <arm_group_label>80mg lurasidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>20mg lurasidone</arm_group_label>
    <arm_group_label>40mg lurasidone</arm_group_label>
    <arm_group_label>80mg lurasidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. After detailed explanations of study objectives, methods and procedures, anticipated
             efficacy, pharmacologic actions, risks and other relevant contents, subjects are aware
             of all relevant information related to this study and have signed the written informed
             consent form voluntarily.

          2. Male subjects are 18≤ age &lt;40 years of age when signing the informed consent.

          3. Subjects with body weight of 50.0≤ and ≤ 80.0 kg and BMI (body mass index) of 19.0≤
             and &lt;24.0 at screening examination.

          4. Subjects are able to comply with all requirements during this study period, receive
             various physical and laboratory examinations per study protocol, and report subjective
             symptoms.

        Exclusion Criteria:

          1. Based on the examination results during screening period, various physical and
             laboratory examinations performed 1 day before medication (Day-1 ) and before
             administration of study drug on the medication day, there are certain medical concerns
             on subject's health status in principal investigator's or study supervising
             physician's opinions (certain treatment or medical observation are deemed necessary).

          2. Subjects with past diabetic history.

          3. Subjects has an HbA1c level of &gt;6.2% at screening.

          4. Subjects with history of gastrointestinal operations.

          5. Because of subjects' past medical history of cardiovascular diseases, liver diseases,
             renal diseases, endocrine disorders, digestive diseases, hematologic diseases,
             respiratory diseases, mental illness, neurological disorders (especially epilepsy and
             other convulsive disorders) and other diseases, subjects are unsuitable to participate
             in this study in the principal investigator's or study supervising physician's
             opinions.

          6. Subjects with past history of allergy to drugs.

          7. Subjects have consumed grapefruit or food containing grapefruit ingredients between 7
             days before medication (Day -7) and administration of study drug on the medication day
             (Day 1). Subjects have consumed food containing hypericum perforatum L. ingredients
             between 14 days before medication (Day-14) and administration of study drug on the
             medication day (Day 1).

          8. Subjects have taken any drugs (including over-the-counter drugs) between 7 days before
             medication (Day_-7) and administration of study drug on medication day.

          9. Regular drinker (criteria are mean daily consumption ≥2 bottles of 640 mL beers or
             Chinese liquor≥150 mL).

         10. Subjects are used to drink large amount (criteria are daily consumption&gt;1.8 L) of
             caffeine-containing beverages (e.g. coffee, black tea, green tea, coca cola or
             nutritional oral solution, etc).

         11. Subjects have history of drug abuse or positive urine drug tests.

         12. Subjects with positive immunologic test results.

         13. Average amount of daily smoking&gt;20 cigarettes.

         14. Subjects have taken other study drugs within 3 months (Day_-90~Day 1) before
             medication.

         15. Subjects received lurasidone orally before.

         16. Subjects have history of blood donations of 400 mL within 3 months (Day_-90~Day 1)
             before medication; 200 mL within 1 month (Day_-30~Day 1) before medication; or
             donation of blood components within 2 weeks (Day_-14~Day 1) before medication.

         17. Subjects have consumed alcohol-containing food between 3 days before medication 3
             (Day_-3) and before administration of study drug on medication day.

         18. Subjects can not tolerate venipuncture or have poor peripheral venous access.

         19. Subjects are unwilling to abstain from vigorous exercise from Day_-1 until discharge.

         20. Other subjects who are unsuitable to participate in this study in principal
             investigator's or study supervising physician's opinions.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ChaoYing Hu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuhui Center Hospital, Shanghai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xuhui Center Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>February 11, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <results_first_submitted>May 31, 2018</results_first_submitted>
  <results_first_submitted_qc>January 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2019</results_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetic</keyword>
  <keyword>lurasidone</keyword>
  <keyword>single dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Total 72 subjects were screened at the clinical site after obtaining informed consent. The data of informed consent from the first subject was march 2014. A total of 37 subjects were enrolled into the study and were randomized to three test drug groups (8 to 20mg group, 8 to 40mg group, 12 to 80mg group), and 9 subjects received placebo.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>20mg Lurasidone</title>
          <description>20mg lurasidone: single oral lurasidone.</description>
        </group>
        <group group_id="P2">
          <title>40mg Lurasidone</title>
          <description>40mg lurasidone: single oral lurasidone.</description>
        </group>
        <group group_id="P3">
          <title>80mg Lurasidone</title>
          <description>80mg lurasidone: single oral lurasidone.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Subjects administered placebo tablet at the same time with each lurasidone group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This study design included 28 men in the positive drug lurasidone group and 9 in placebo group. All subjects who received lurasidone or placebo were included in the safety population. All subjects who received lurasidone and have evaluable PK data were included in the PK analysis population.</population>
      <group_list>
        <group group_id="B1">
          <title>20mg Lurasidone</title>
          <description>20mg lurasidone: single oral lurasidone.</description>
        </group>
        <group group_id="B2">
          <title>40mg Lurasidone</title>
          <description>40mg lurasidone: single oral lurasidone.</description>
        </group>
        <group group_id="B3">
          <title>80mg Lurasidone</title>
          <description>80mg lurasidone: single oral lurasidone.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Subjects administered placebo tablet at the same time with each lurasidone group.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.5" spread="3.74"/>
                    <measurement group_id="B2" value="25.4" spread="3.07"/>
                    <measurement group_id="B3" value="27.5" spread="7.79"/>
                    <measurement group_id="B4" value="28.4" spread="4.72"/>
                    <measurement group_id="B5" value="27.1" spread="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone Cmax</title>
        <description>Cmax：Maximum (peak) observed drug serum concentration.</description>
        <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <population>ALL 28 subjects who received lurasidone and have evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>20mg Lurasidone</title>
            <description>20mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O2">
            <title>40mg Lurasidone</title>
            <description>40mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O3">
            <title>80mg Lurasidone</title>
            <description>80mg lurasidone: single oral lurasidone.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone Cmax</title>
          <description>Cmax：Maximum (peak) observed drug serum concentration.</description>
          <population>ALL 28 subjects who received lurasidone and have evaluable PK data.</population>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" spread="35.4"/>
                    <measurement group_id="O2" value="50.9" spread="29.6"/>
                    <measurement group_id="O3" value="113" spread="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone AUC</title>
        <description>AUC：Area under the serum concentration-time curve</description>
        <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>20mg Lurasidone</title>
            <description>20mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O2">
            <title>40mg Lurasidone</title>
            <description>40mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O3">
            <title>80mg Lurasidone</title>
            <description>80mg lurasidone: single oral lurasidone.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone AUC</title>
          <description>AUC：Area under the serum concentration-time curve</description>
          <units>ng･h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.3" spread="26.3"/>
                    <measurement group_id="O2" value="151" spread="26.6"/>
                    <measurement group_id="O3" value="322" spread="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-t</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" spread="26.2"/>
                    <measurement group_id="O2" value="163" spread="26.5"/>
                    <measurement group_id="O3" value="353" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-∞</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" spread="26.3"/>
                    <measurement group_id="O2" value="174" spread="26.5"/>
                    <measurement group_id="O3" value="378" spread="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone Tmax</title>
        <description>Tmax：Time to maximum (peak) drug serum concentration</description>
        <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>20mg Lurasidone</title>
            <description>20mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O2">
            <title>40mg Lurasidone</title>
            <description>40mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O3">
            <title>80mg Lurasidone</title>
            <description>80mg lurasidone: single oral lurasidone.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone Tmax</title>
          <description>Tmax：Time to maximum (peak) drug serum concentration</description>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.5" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.50" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone λZ</title>
        <description>λZ：Elimination rate constant</description>
        <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>20mg Lurasidone</title>
            <description>20mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O2">
            <title>40mg Lurasidone</title>
            <description>40mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O3">
            <title>80mg Lurasidone</title>
            <description>80mg lurasidone: single oral lurasidone.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone λZ</title>
          <description>λZ：Elimination rate constant</description>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0271" spread="26"/>
                    <measurement group_id="O2" value="0.0383" spread="32.9"/>
                    <measurement group_id="O3" value="0.0383" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone t1/2</title>
        <description>t1/2 :Biological half life correlated with the elimination rate constant (kel) of semi-logarithmic concentration-time curve</description>
        <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>20mg Lurasidone</title>
            <description>20mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O2">
            <title>40mg Lurasidone</title>
            <description>40mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O3">
            <title>80mg Lurasidone</title>
            <description>80mg lurasidone: single oral lurasidone.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone t1/2</title>
          <description>t1/2 :Biological half life correlated with the elimination rate constant (kel) of semi-logarithmic concentration-time curve</description>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="26"/>
                    <measurement group_id="O2" value="18.1" spread="32.9"/>
                    <measurement group_id="O3" value="18.1" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone MRT</title>
        <description>MRT：Mean residence time.</description>
        <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>20mg Lurasidone</title>
            <description>20mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O2">
            <title>40mg Lurasidone</title>
            <description>40mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O3">
            <title>80mg Lurasidone</title>
            <description>80mg lurasidone: single oral lurasidone.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone MRT</title>
          <description>MRT：Mean residence time.</description>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="26.3"/>
                    <measurement group_id="O2" value="11.1" spread="21.5"/>
                    <measurement group_id="O3" value="11.7" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone CL/F</title>
        <description>CL/F：Apparent total clearance.</description>
        <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>20mg Lurasidone</title>
            <description>20mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O2">
            <title>40mg Lurasidone</title>
            <description>40mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O3">
            <title>80mg Lurasidone</title>
            <description>80mg lurasidone: single oral lurasidone.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone CL/F</title>
          <description>CL/F：Apparent total clearance.</description>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187" spread="26.3"/>
                    <measurement group_id="O2" value="231" spread="26.5"/>
                    <measurement group_id="O3" value="212" spread="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lurasidone VZ/F</title>
        <description>VZ/F: Apparent volume of distribution at terminal phase (correlated with λz)</description>
        <time_frame>pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>20mg Lurasidone</title>
            <description>20mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O2">
            <title>40mg Lurasidone</title>
            <description>40mg lurasidone: single oral lurasidone.</description>
          </group>
          <group group_id="O3">
            <title>80mg Lurasidone</title>
            <description>80mg lurasidone: single oral lurasidone.</description>
          </group>
        </group_list>
        <measure>
          <title>Lurasidone VZ/F</title>
          <description>VZ/F: Apparent volume of distribution at terminal phase (correlated with λz)</description>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6887" spread="36.3"/>
                    <measurement group_id="O2" value="6022" spread="41.8"/>
                    <measurement group_id="O3" value="5523" spread="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From just after use of the study drug to the study-ending evaluation, up to 11 days.</time_frame>
      <desc>All 37 subjects who received lurasidone or placebo were included in the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>20mg Lurasidone</title>
          <description>20mg lurasidone: single oral lurasidone.</description>
        </group>
        <group group_id="E2">
          <title>40mg Lurasidone</title>
          <description>40mg lurasidone: single oral lurasidone.</description>
        </group>
        <group group_id="E3">
          <title>80mg Lurasidone</title>
          <description>80mg lurasidone: single oral lurasidone.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Subjects administered placebo tablet at the same time with each lurasidone group.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood prolactin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof.Hu Chaoying</name_or_title>
      <organization>Shanghai Xuhui Central Hospital, Drug Clinical Trial Institution</organization>
      <phone>13816319160</phone>
      <email>cyhu@shxh-centerlab.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

